Pharmacy Daily | AZ signs Adelaide Uni deal

University of Adelaide researchers are being given access to fifty of global pharma giant AstraZeneca’s (AZ) drug compounds to study new therapies in a groundbreaking new collaboration, the university has announced. Adelaide Research and Innovation (ARI), the University of Adelaide’s commercialisation arm, sealed the agreement which is a first for South Australia. ARI Deputy Director Dr Jane Rathjen said the partnership will “allow for access to optimised compounds, technologies, multidisciplinary science, services and know-how to speed up research outcomes, and most importantly the opportunity to see ideas develop into treatments for patients.” AstraZeneca and ARI will also fund successful research proposals that result from the partnership. Therapy areas covered include cardiovascular, metabolic, respiratory, oncology, autoimmune & infection and neuroscience, with AZ to have first rights to commercialise any discovery made by the university researchers. The collaboration is based on AstraZeneca’s Open Innovation platfrom, which takes new and existing compounds out of the company’s laboratories and into the hands of research centres. “Furthering the boundaries of science is at the core of what AstraZeneca does, so we’re absolutely delighted to be supporting University of Adelaide researchers who have the potential to find exciting new developments in medicine thanks to this collaboration,” said AZ Australia president Paul Spittle.

---

The above article was sent to subscribers in Pharmacy Daily's issue from 03 Jul 15
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Jul 15